Biologics in paediatric Crohn's disease

Area of Science:

• Pediatric Gastroenterology
• Immunology
• Clinical Pharmacology

Background:

• Childhood-onset Crohn's disease is increasingly prevalent and often more severe than adult-onset.
• Pediatric Crohn's disease significantly impacts children's quality of life and growth.
• Therapeutic strategies in children must consider unique toxicity risks and long-term outcomes.

Purpose of the Study:

• To review the efficacy and safety of biologic therapies in pediatric Crohn's disease.
• To highlight the benefits of biologics for disease control and growth in children.
• To identify gaps in knowledge regarding long-term risks and outcomes of biologics in pediatric patients.

Main Methods:

• Review of existing literature and case series on biologic drug use in children with Crohn's disease.
• Analysis of data on disease activity control, growth parameters, and adverse events.
• Assessment of available information on specific biologic agents like infliximab, adalimumab, certolizumab, and natalizumab.

Main Results:

• Biologic therapies show promising results in controlling pediatric Crohn's disease activity and improving growth.
• Short-term adverse reactions to biologics in children appear infrequent.
• Loss of response is a notable long-term challenge, particularly in pediatric populations.

Conclusions:

• Biologics offer significant advantages for managing pediatric Crohn's disease, especially when conventional therapies fail.
• While short-term safety is generally favorable, extensive long-term data is still required.
• Current data limitations should not impede access to essential biologic treatments for children with refractory disease.